Form 8-K BIOGEN INC. For: Apr 22
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
SunTrust Defends Biogen (BIIB); 'Buy on Weakness'
April 22, 2020 10:12 AM EDTSunTrust analyst Robyn Karnauskas reiterated a Buy rating and $360.00 price target on Biogen (NASDAQ: BIIB), telling clients to 'buy on weakness'
Karnauskas notes the company updated their Alzheimer's Disease (AD) filing timelines from early 2020 to a rolling BLA, with completion by 3Q20,... More
Biogen (BIIB) 6% Lower as Aducanumab Timeline Pushed Out
April 22, 2020 7:50 AM EDTBiogen (NASDAQ: BIIB) is down 6% in pre-open trading despite strong results as the company said it stated submitting modules for aducanumab BLA and expects the U.S. filing in the third quarter, which pushes out the launch timelines.
... More